Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nikotiinhape - düslipideemiad - lipiidi modifitseerivad ained - pelzont on näidustatud ravi dyslipidaemia, eriti patsientidel, kellel on kombineeritud segatud dyslipidaemia (mida iseloomustab kõrgenenud low-density-lipoproteiin (ldl) kolesterooli ja triglütseriidide ja madala high-density-lipoproteiin (hdl)kolesterooli) ja patsientidel, kellel on esmane hypercholesterolaemia (heterozygous perekondliku ja mitte-perekondlik). pelzont tuleks kasutada patsientidel kombineerituna 3-hüdroksü-3-methylglutaryl-koensüüm-a (hmg-coa)-reduktaasi inhibiitorid (statins), kui kolesterooli alandav mõju ja hmg-coa-reduktaasi inhibiitor monotherapy on ebapiisav. seda saab kasutada nii monotherapy ainult patsientidel, kellele hmg-coa-reduktaasi inhibiitorid, loetakse sobimatuks või ei ole talutav. dieedi ja muude mittefarmakoloogiliste raviviiside e. treening, kehakaalu vähendamine) tuleks jätkata ravi ajal koos pelzont.

Euroopa Liit - eesti - EMA (European Medicines Agency)

recordati rare diseases - toksofersolaan - cholestasis; vitamin e deficiency - vitamiinid - vedrop on näidustatud malabsorptsioonist lastel kaasasündinud puudulikkuse või pärilik krooniline kolestaas, alates sünnist (ajalised vastsündinud) ja e-vitamiini puudus-16 – 18 eluaastat, piirkonniti.

Euroopa Liit - eesti - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Euroopa Liit - eesti - EMA (European Medicines Agency)

abbvie ltd - naatriumdasabuviir - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - exviera on näidustatud kombinatsioonis teiste ravimitega kroonilise c-hepatiidi (khk) täiskasvanute raviks. c-hepatiidi viiruse (hcv) genotüüp spetsiifiline aktiivsus.

Eesti - eesti - Adama

adama - vees dispergeeruvad graanulid - metribusiin - herbitsiidid

Eesti - eesti - Ravimiamet

astra tech ab - baariumsulfaat - suukaudne suspensioon - 2,4g 1ml 340g 1tk; 2,4g 1ml 340g 24tk

Eesti - eesti - Ravimiamet

teva b.v. - tiotroopium - inhalatsioonipulber kõvakapslis - 10mcg 60tk; 10mcg 15tk; 10mcg 30tk

Eesti - eesti - Adama

adama - emulsioonikontsentraat - fenpropidiin + prokloraas + tebukonasool - fungitsiidid

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Eesti - eesti - Adama

adama - emulsioonikontsentraat - prokloraas - fungitsiidid